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Aerobic glycolysis enables cancer cells to rapidly take up nutrients (e.g., nucleotides, 
amino acids, lipids) and incorporate them into the biomass needed to produce a new 
cell. In contrast to existing chemotherapy/radiotherapy strategies, inhibiting aerobic 
glycolysis to limit ATP yield is a highly efficient approach for suppressing tumor cell 
proliferation. However, most, if not all, current inhibitors of aerobic glycolysis cause 
significant adverse effects, due to their nonspecific delivery and distribution to 
non-diseased organs, low bioavailability and a narrow therapeutic window. New 
strategies to enhance the biosafety and efficacy of these inhibitors are needed for 
moving them into clinical application. To address this need, we developed a liposomal 
nanocarrier functionalized with a well-validated tumor targeting peptide to 
specifically deliver the aerobic glycolysis inhibitor 3-bromopyruvate (3-BP) into 
tumor tissue. The nanoparticles effectively targeted tumors after systemic 
administration into tumor-bearing mice, and suppressed tumor growth by locally 
releasing 3-BP to inhibit ATP production of the tumor cells. No overt side effects were 
observed in the major organs. This report demonstrates the potential utility of the 
nanoparticle-enabled delivery of an aerobic glycolysis inhibitor as an anticancer 
therapeutic agent.  
 




Unlike normal differentiated cells that rely primarily on mitochondrial oxidative 
phosphorylation to generate the adenosine 5´-triphosphate (ATP) needed for cellular 
processes 1,2, tumor cells rely on aerobic glycolysis, a phenomenon termed the 
“Warburg effect.” 3-5. Aerobic glycolysis is an inefficient way to generate ATP, 
however, it facilitates the uptake and incorporation of nutrients needed for tumor cell 
proliferation, such as nucleotides, amino acids, and lipids, into the biomass 4. There is 
 growing evidence that inhibiting aerobic glycolysis can directly induce tumor cell 
apoptosis through reducing ATP levels. The pyruvate mimetic 3-bromopyruvate (3-BP) 
is considered to be an effective inhibitor of glycolysis 6, 7, and has shown remarkable 
efficacy in inducing tumor cell apoptosis and preventing tumor growth in preclinical 
studies 8-11. 3-BP is taken up into tumor cells via monocarboxylate transporter 1 
(MCT1) which is overexpressed in most tumor cells, especially in hypoxic tumor 
regions 12-14. Despite 3-BP showing considerable therapeutic potential against tumors, 
significant side effects, mainly owing to nonspecific delivery, distribution to 
non-diseased organs, low bioavailability and narrow therapeutic window, limit its 
clinical application 15. 
For in vivo use, the ideal scenario would be targeted delivery of therapeutic 3-BP 
to cancer cells that have particularly high expression of MCT1, thereby limiting side 
effects that result from nonspeciﬁc delivery as well as reducing the therapeutic dosage. 
Motivated by this rationale, we constructed biodegradable and biocompatible 
liposomal nanoparticles for the targeted delivery of 3-BP agent to tumors (Figure 1). 
We chose US Food and Drug Administration (FDA)-approved liposome components 
to construct the nanoparticles, thereby facilitating the translation of this nanovehicle 
into clinical practice 16-19. We encapsulated 3-BP into nanoparticles using a 
filming-rehydration method, and covalently coupled a tumor targeting pentapeptide 
(Cys-Arg-Glu-Lys-Ala; CREKA) to their surface. CREKA recognizes 
fibrin-fibronectin complexes (microthrombi) which are specific for the tumor vascular 
endothelium, enabling the peptide-linked nanoparticles to accumulate at the site of the 
tumor in a self-amplifying manner 20, 21. The resulting nanoformulation (T-Lipo-3BP) 
effectively targeted to tumor vessels following systemic administration and released 
3-BP to selectively kill tumor cells by blocking ATP production (Figure 1). This 
approach not only inhibited the growth of the tumor, but showed no or minimal side 
effects, unlike free 3-BP. Our strategy allows 3-BP to be delivered safely and more 
effectively than free drug, and paves the way for its potential clinical usage. 
 
 
 2. Materials and Methods 
Materials 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000] (DSPE-PEG-2000) and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene 
glycol)-3400] (DSPE-PEG-3400-Mal) were purchased from Nuodepaisen Medical 
Technology Co. Ltd. (Suzhou, China). The peptide CREKA was synthesized by Taopu 
Biotechnology Co. Ltd (Shanghai, China). 3-Bromopyruvate (3-BP) was purchased 
from Beijing Inoke Technology Co. Ltd (Beijing, China). Cell counting kit-8 was 
purchased from Dojindo Molecular Technologies (Tokyo, Japan). 
Anti-Monocarboxylic acid transporter 1 antibody (Abcam: ab90582) and 
anti-HIF-1-alpha antibody (Abcam: ab16066) were obtained from Youningwei 
Biotechnology Co., Ltd (Shanghai, China). 
2.1. Synthesis of DSPE-PEG-CREKA 
DSPE-PEG-CREKA was prepared according to methods described in our previous 
work 22. Briefly, 8.5 mg DSPE-PEG-MAL and 1.78 mg CREKA peptide were 
dissolved in 4 mL of 10% methanol and stirred for 24 h at room temperature under 
anaerobic conditions. The solution was then dialyzed (molecular weight cutoff of Mr 
1000) against tri-distilled water for 24 h and lyophilized for 48h.  
2.2. Preparation and characterization of nanoparticles 
T-Lipo-3BP and T-Lipo were prepared by a modified filming-rehydration method 22. 
In brief, 20 mg of lecithin, 2.36 mg of DSPE-PEG-2000, 2.36 mg of 
DSPE-PEG-CREKA and 4.9 mg of cholesterol were dissolved in 10 mL of 
dichloromethane in a round-bottom flask. After rotary evaporation for 40 min, a thin 
transparent film was formed. Phosphate-buffered saline (PBS) (10 mL) with varying 
amounts of 3-BP was added, and hydration was carried out for 20 min at 50ºC. The 
final product was filtered using a 200 µm liposome extruder. Free 3-BP was then 
removed by 24 h of ultrafiltration (MWCO: 2000). The final solution was collected 
and used for characterization of the nanoparticles, drug release profile tests and in 
vivo experiments. For in vivo imaging, 3-BP was replaced with Cy7 fluorescent dye 
 during the synthetic process. The size distribution and zeta potential of T-Lipo and 
T-Lipo-3BP were assessed by dynamic light scattering (DLS) using a ZetaSizer Nano 
series Nano-ZS (Malvern Instruments Ltd., Malvern, UK). The morphology of 
T-Lipo-3BP and T-Lipo was characterized using transmission electron microscopy 
(TEM) with a negative staining method as previously described 22 and using a 
EM-200CX electron microscope (JEOL Ltd., Tokyo, Japan). 
2.3. In vitro drug release profile of T-Lipo-3BP 
The in vitro drug release kinetic profile of T-Lipo-3BP was evaluated by dialysis. 
Briefly, 2 mL of T-Lipo-3BP was added to a dialysis bag (molecular weight cutoff of 
Mr 1000) and placed into 40 mL of PBS at pH 7.4 or pH 6.8 in a 50 mL tube. The tube 
was shaken at 37ºC. At various times, 1 mL of the outside buffer was removed and 
replaced with 1 mL of fresh PBS. The amount of 3-BP contained in the PBS was 
assayed using high-performance liquid chromatography (HPLC). In brief, a C18-alkyl 
reverse phase bonded column was chosen as the stationary phase. The mobile phase 
contained a 90/10 mixture of 0.1% trifluoroacetic acid in water/0.1% trifluoroacetic 
acid in acetonitrile. An isocratic elution method with a flow rate of 1 mL per minute 
and a run time of 5 minutes was used. 3-BP levels were assessed by measuring the 
absorbance using an ultraviolet detector at 204 nm. A standard curve for 3-BP was 
generated using drug concentrations of 0.1875, 0.375, 0.75, 1.5 and 3 mg/mL. 
Samples were analyzed in triplicate and solvent alone was used as the blank. 
2.4. Cytotoxicity assays  
The mouse pancreatic cancer cell line Pan-02 was kindly supplied by Professor H. 
Lee from Moffitt Cancer Center and Research Institute, Tampa, USA, and maintained 
at 37ºC and 5% CO2 in RPMI1640 medium supplemented with 10% Fetal Bovine 
Serum (FBS) and 1% penicillin and streptomycin. The human breast cancer cell line 
MDA-MB-231 was purchased from China Infrastructure of Cell Line Resources 
(Peking Union). Mouse primary testis stromal cells (MTS) were isolated from 
immature mice as previously described 23 and were maintained at 37ºC and 5% CO2 
in DMEM supplemented with 10% FBS and 1% penicillin and streptomycin. 
Authentication of the MDA-MB-231 cell line was performed by short tandem repeat 
 DNA profiling and compared with a reference database. All the cell lines used in this 
work were shown to be free of mycoplasma contamination. For the cytotoxicity assay, 
the cell lines were seeded into 96-well plates at 37ºC and sub-cultured for 24 h. The 
cell cultured medium was subsequently replaced by fresh medium containing different 
3-BP concentrations at different conditions. After further incubation for 24 h, the cell 
viability was assessed using a CCK-8 Kit assay.  
2.5. Measurement of ATP levels 
Pan-02 pancreatic cancer cells (1 x 106) were seeded into 6-well plates and cultured at 
37ºC in 5% CO2 for 24 h. The medium was then replaced by a fresh medium 
containing 20 or 40 µM 3-BP. After incubation at 37ºC for 6 or 12 h, the cultured cells 
were collected and ATP was measured using an Enhanced ATP Assay Kit（Beyotime: 
S0027） according to the manufacturer’s instructions. For assessing intratumoral ATP 
levels, tumor tissues were harvested from pancreatic cancer tumor-bearing C57BL 
mice and analyzed according to the Enhanced ATP Assay Kit protocol.  
2.6. Animal experiments 
To evaluate the in vivo anti-tumor efficacy of T-Lipo-3BP, a mouse tumor model 
was established by inoculating 1 × 106 Pan-02 tumor cells into the right flank of 
C57BL/6 mice. The mice were divided into five groups, with six animals in each 
group. When the tumor volume reached approximately 150 mm3 (volume = length × 
width2/2), different drug formulations were injected intravenously into the mice.  
For in vivo imaging experiments, Pan-02 tumor-bearing nude mice were injected 
intravenously with T-Lipo-3BP-Cy7. After 2 and 24 h, the biodistribution of 
nanoparticles was evaluated using a Maestro TM in vivo optical imaging system.  
To assess the potential side effects of T-Lipo-3BP, C57BL mice bearing Pan-02 
tumors were randomly divided into 5 groups: saline, 3-BP, T-Lipo-3BP, T-Lipo and 
Lipo-3BP. Meanwhile, the normal mice were used for healthy control. The mice were 
treated on three occasions at two day intervals. Two days after the final treatment, the 
mice were euthanized. Serum was collected for biochemical analysis and the major 
organs were resected for histopathology. 
All animal procedures were approved by the Committee on the Ethics of Animal 
 Experiments of the Health Science Center of Peking University (Beijing, China). 
2.7. Western blotting 
After treatment with varying drug concentrations, cells were harvested and lysed in 
RIPA buffer. The expression of MCT1 was subsequently analyzed by western blotting. 
Total protein (20 g) was separated on 10% polyacrylamide gels and proteins were 
transferred to a polyvinylidene fluoride (PVDF) membrane.  
2.8. Statistical analysis 
Statistical analysis was conducted using the student t-test for comparison of two 
groups and one-way ANOVA for multiple groups, followed by Newman-Keuls test. A 
P value of less than 0.05 was considered significant. 
 
3. Results and Discussion  
3.1. Preparation and characterization of T-Lipo-3BP nanoparticles 
To construct liposomal nanoparticles that target the tumor vasculature, we first 
conjugated the tumor targeting peptide CREKA to DSPE-PEG-MAL by the Michael 
addition reaction between the thiol of the peptide cysteine and the maleimide at the 
PEG terminus of the lipid monomer (Figure S1). The successful synthesis of 
DSPE-PEG-CREKA was confirmed using matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF-MS) and nuclear magnetic resonance 
(NMR) analyses. The molecular weight of DSPE-PEG-MAL increased from 3800 to 
4402 following peptide conjugation, as measured by MALDI-TOF-MS (Figure S2). 
Furthermore, the characteristic peaks of DSPE, PEG and MAL were clearly detected 
by NMR spectroscopy in the DSPE-PEG-MAL sample (Figure S3A), while the MAL 
peak disappeared following the CREKA conjugation (Figure S3B). The CREKA 
peptide coated liposome nanoparticles loaded with 3-bromopyruvate (3-BP) were 
subsequently prepared using a thin-film dispersion hydration method, as described by 
us previously [22]. To optimize the drug loading efficiency, three different mass ratios 
of lipid to 3-BP drug were tested (i.e. 20:15, 20:17 and 20:20). Drug encapsulation 
efficiency was highest (47.23%) when the ratio of lipid to 3-BP was 20:17 (Table S1), 
and this ratio was chosen for subsequent studies. Transmission electron microscopy 
 (TEM) showed that the empty (T-Lipo) and drug-loaded (T-Lipo-3BP) liposomal 
nanoparticles had a typical spherical structure (Figure 2A and 2C). Dynamic light 
scattering (DLS) analysis revealed a rather uniform size distribution for both 
nanoparticles, with a slight increase in the average hydrodynamic diameter from 
141.5 nm for T-Lipo to 160.5 nm for T-Lipo-3BP (Figures 2B and 2D) and the PDI 
were 0.169 and 0.090 respectively. 
We next investigated the 3-BP release profile of the liposomes in vitro by 
measuring the absorbance in the dialysate at 204 nm using high-performance liquid 
chromatography (HPLC). At pH 6.8, approximately 80% of the 3-BP was released 
from the T-Lipo-3BP nanoparticles within the first 30 h (Figure 2E), while less than 
60% of drug was released over the same period at pH 7.4. Based on this 
pH-dependent drug release pattern, an enhanced tumor specific release of 3-BP 
following binding of T-Lipo-3BP to fibrin-fibronectin complexes (microthrombi) on 
tumor vascular wall would be expected due to the low pH of the tumor 
microenvironment. In addition, the stability of T-Lipo-3BP was investigated by 
labeling the nanoparticles with membrane dye Dio (green) whose fluorescence is only 
detectable when inserted into an intact lipid layer. After incubating the nanoparticles 
in serum for 48 h, there was a slight decrease (about 15%) in fluorescent intensity 
(Figure 2F), demonstrating that the structural integrity of the particles was 
maintained. 
 
3.2. MCT1-dependent in vitro cytotoxicity of T-Lipo-3BP 
Monocarboxylate transporter 1 (MCT1), which is particularly highly expressed under 
hypoxic conditions, such as those found in the tumor microenvironment, is reported to 
mediate the cellular uptake of 3-BP in tumor cells [12-14]. To investigate the role of 
MCT1 in the uptake of T-Lipo-3BP-derived 3-BP, we first examined MCT1 
expression in pancreatic cancer cells (Pan-02) and found that it was indeed more 
highly expressed under hypoxic conditions than in normoxia (Figure S4A). 
Consistent with this result, the viability of Pan-02 cells was reduced by approximately 
20% and 50% following treatment with T-Lipo-3BP containing 20 µM or 40 µM of 
 3-BP, respectively for 24 h, but only under hypoxic conditions (Figure 3A). The 
effect was stronger at pH 6.8 than at pH 7.4. These data together demonstrate that the 
combination of hypoxia and lower pH led to the most cell killing. 
To determine whether T-Lipo-3BP kills tumor cells in a MCT1 dependent 
manner, we investigated the effect of T-Lipo-3BP treatment on other two cell lines, 
the human breast cancer cell line MDA-MB-231, and mouse testis stromal cells 
(MTS), which have low 6 (Figure S4B&C), and negligible (Figure S4D) MCT1 
expression, respectively. Cell viability assays showed that even at 3-BP 
concentrations in T-Lipo-3BP as high as 56 µM, 100% of MDA-MB-231 and MTS 
cells remained viable after 24 h of treatment at pH 7.4 under hypoxic conditions 
(Figure 3B,C). However, almost all Pan-02 cells were dead under the same 
conditions. Taken together, these data suggest that T-Lipo-3BP cytotoxicity is closely 
associated with the MCT1 expression levels in tumor cells and testis stromal cells.  
We next examined whether T-Lipo-3BP killed MCT1-positive tumor cells by 
inhibition of aerobic glycolysis. An enhanced ATP assay revealed that, after treating 
Pan-02 cells with T-Lipo-3BP containing 20 µM or 40 µM of 3-BP for 6 or 12 h, 
T-Lipo-3BP significantly reduced the cellular ATP content in a concentration and 
time-dependent manner (Figure 3D). This suggests that ATP production from aerobic 
glycolysis was effectively blocked by T-Lipo-3BP treatment, and that this was the 
likely mechanism of cell death.  
 
3.3. In vivo tumor targeting of T-Lipo-3BP 
The ability to target cytotoxic agents direct to tumors plays a decisive role in efficient 
cancer therapy. To investigate the tumor targeting capability of T-Lipo-3BP, we 
examined the biodistribution of Cy7-labeled nanoparticles after intravenous 
administration into Pan-02 tumor-bearing mice. Two hours after nanoparticle 
administration, in vivo imaging showed a weak fluorescence signal over much of the 
mouse body, but there was a very strong fluorescence signal at the site of the tumor 
(Figure 4A). After 24 h, a strong fluorescence signal remained within the tumor region, 
but much less fluorescence was detected in other regions, confirming highly effective 
 tumor targeting in vivo. 
 
3.4. In vivo anti-tumor activity of T-Lipo-3BP  
A prerequisite for in vivo anti-tumor activity of T-Lipo-3BP is that the target tumor 
expresses MCT1. We thus performed ex vivo immunohistochemistry of Pan-02 tumor 
tissue from our murine model and showed that the core of the tumors (~150 mm3) had 
higher MCT1 expression, the same area where significant hypoxia-inducible factor 1 
(HIF-1) expression was observed (Figure S5). This confirmed that the central region 
of the tumors was highly anaerobic and that the model was an effective target for 3-BP. 
The Pan-02 pancreatic tumor-bearing mice were then injected intravenously with 
different formulations, including free 3-BP, targeted empty nanoparticles (T-Lipo), 
nontargeted drug-loaded nanoparticles (Lipo-3BP) or T-Lipo-3BP (3-BP), every two 
days for a total of 8 injections. The tumor volume was measured every 6 days using 
vernier calipers. Compared with saline and T-Lipo, the growth of tumors was 
significantly inhibited by 3-BP, Lipo-3BP or T-Lipo-3BP (Figure 4B). Clearly, 
T-Lipo-3BP at the same dosage outperformed free drug and Lipo-3BP, and 
dramatically reduced the tumor volume. Tumor mass was also assessed two days after 
the last treatment (Figure 4C). Mice injected with T-Lipo-3BP had a small tumor 
burden in contrast to the other groups, as demonstrated by a significant reduction in 
tumor weight. Together, these results demonstrate that T-Lipo-3BP effectively targets 
to tumors and inhibits their growth. 
To examine the mechanism by which T-Lipo-3BP killed tumor cells, we evaluated 
apoptosis in the tumor tissue using terminal deoxynucleotidyl transferase-mediated 
deoxyuridine triphosphate nick-end labeling (TUNEL). TUNEL-positive cells were 
much more abundant in T-Lipo-3BP-treated tumors than in the other groups (Figure 
S6). We also observed that T-Lipo-3BP significantly reduced intratumoral ATP 
production (Figure 4D), while free 3-BP treatment only decreased the ATP level 
slightly. 
 
3.5. In vivo tolerability of T-Lipo-3BP  
 The in vivo safety of T-Lipo-3BP was evaluated using normal C57BL mice. After 
intravenous administration of T-Lipo-3BP on three occasions at two day intervals, no 
loss of body weight was detected, with a similar result to the saline control group 
(Figure S7). We also performed histological examination of the major organs 
including the heart, liver, spleen, lung and kidney. Systemic administration of 
T-Lipo-3BP did not induce damage in any of the organs examined (Figure 5A), while 
administration of free 3-BP resulted in some adverse pathology in the liver. This is 
notable because serious liver burden is the dose-limiting side effect of free 3-BP in the 
clinical setting. We further investigated whether T-Lipo-3BP treatment resulted in 
functional abnormalities in the major organs of mice by assessing serum 
concentrations of biochemical indicators of liver, heart and renal function. Following 
three doses of T-Lipo-3BP, no significant changes in any of the indicators were 
observed compared with saline group. In contrast, free 3-BP significantly increased 
total bilirubin (TBIL; a well-known marker of liver cell damage) in the serum 
(Figures 5B and S8).  
 
4. Conclusions 
In summary, we have developed a tumor vascular endothelium targeted liposome 
nanoparticle (T-Lipo-3BP) to specifically deliver the aerobic glycolysis inhibitor 3-BP 
to MCT1-overexpressing tumors in mice. We chose liposomes as the controlled 
release system because its safety in clinical use has been well established. T-Lipo-3BP 
nanoparticles were able to efficiently and safely deliver 3-BP to the tumor following 
systemic administration and therefore represent a promising vehicle targeting the 
aerobic glycolysis pathway of tumor cells overexpressing MCT1. The lack of 
detectable severe side effects, especially the hepatotoxicity that is characteristic of 
3-BP, marks a major improvement over the current free aerobic glycolysis inhibitors. 
We believe that this technique not only provides an effective strategy for the clinical 
application of 3-BP, but also could be applied for the delivery of other aerobic 
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Figure 1. The construction of T-Lipo-3BP nanoparticles and the proposed 
mechanism of action in tumor vessels. (A) Schematic illustration of synthesis of the 
T-Lipo-3BP nanoparticles and the encapsulation of the glycolysis inhibitor 3-BP. (B) 
After intravenous administration of T-Lipo-3BP into tumor-bearing mice, T-Lipo-3BP 
targets to the tumor vascular wall and locally releases 3-BP. The released drug is then 
delivered into tumor cells via the transporter MCT1, and subsequently inhibits 
hexokinase-2 (HK-2). This in turn blocks ATP supply for tumor cells without 
 affecting normal cells. 
 
 
Figure 2. Characterization of T-Lipo-3BP nanoparticles. (A,C) TEM images of 
representative empty (A) and drug-loaded (C) liposomal nanoparticles. Scale bars are 
200 nm. (B,D) DLS analysis showing the size distribution of empty (B) and 
drug-loaded (D) liposomal nanoparticles. (E) In vitro release kinetics of 3-BP from 
T-Lipo-3BP at different pH values (pH 6.8 is characteristic of the tumor 
microenvironment; pH 7.4 represents physiological conditions in the blood). Data 
represent the mean ± s.d. of three independent experiments. (F) In vitro stability of 
Dio-labeled T-Lipo-3BP. The nanoparticles are quite stable over time in serum at 
pH7.4. Representative results of three independent experiments are shown. 
 
  
Figure 3. Effects of T-Lipo-3BP on cell viability and ATP production. (A) Viability 
of Pan-02 tumor cells after treatment with T-Lipo-3BP containing 40 µM or 20 µM 
3-BP under both normoxic and hypoxic conditions at pH 7.4 and 6.8 at 37°C for 24 h. 
*p<0.05, **p<0.01, ***p<0.001. Error bars represent the mean ± s.d. of three 
independent experiments. (B) Cytotoxicity of T-Lipo-3BP contaning different 
concentrations of 3-BP in Pan-02 and MDA-MB-231 tumor cell lines after 24 h of 
treatment at pH 7.4 under hypoxic conditions. (C) Cytotoxicity of T-Lipo-3BP 
containing different concentrations of 3-BP in Pan-02 tumor cells and MTS cells after 
24 h of treatment at pH 7.4 under hypoxic conditions. (D) Cellular levels of ATP after 
treatment of Pan-02 cells with different concentrations of 3-BP in T-Lipo-3BP. Error 
bars represent the mean ± s.d. of three independent experiments, ***p<0.001. 
 
  
Figure 4. In vivo tumor targeting and anti-tumor activity of T-Lipo-3BP. (A) In 
vivo imaging of Pan-02 tumor-bearing mice 2 and 24 h after administration of 
Cy7-labeled T-Lipo-3BP. Black circles indicate the site of the tumors. (n = 3). (B) The 
size of the tumors was recorded at different time points after intravenous 
administration of various drug formulations. Data are presented as mean ± s.d. (n = 6). 
(C) Tumors were harvested two days after the last treatment and weighed. Data are 
presented as the mean ± s.d. (n = 3). (D) Intratumoral ATP levels were measured in 
tumors harvested two days after the last treatment with different drug formulations. 
Data are presented as the mean ± s.d. (n = 3). *p<0.05, **p<0.01, ***p<0.001. 
  
Figure 5. Safety evaluation of T-Lipo-3BP in vivo. (A) H&E staining of major 
organs removed two days following the final treatment with various drug 
formulations. Some hepatic damage (indicated by the dotted line) was apparent in the 
group treated with free 3-BP. The images are representative of three independent 
experiments. (B) After intravenous administration of various drug formulations, 
whole blood was drawn from retro-orbital venous plexus of wild-type C57BL mice 
and serum was analyses for various markers of tissue injury. Data represent the mean 
± s.d. (n = 6). 
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